| BSX |
Report |
Organic revenue growth (Q2'26) |
BEAT |
pred ~7.5% vs. cons 5.3% |
MEDIUM |
| BSX |
Report |
Adjusted EPS (Q2'26) |
BEAT |
pred ~$0.86 vs. cons $0.83 |
MEDIUM |
| BSX |
Report |
Total reported revenue (Q2'26) |
BEAT |
pred ~$5.46B vs. cons ~$5.40B |
MEDIUM |
| BSX |
Guide |
FY26 organic revenue growth guide |
UNCHANGED |
guide ~6.5-8.0% (reaffirmed) vs. cons ~7.0% (FY26) |
MEDIUM |
| BSX |
Guide |
FY26 adjusted EPS guide |
BETTER |
guide ~$3.36-$3.43 vs. cons ~$3.38 (FY26) |
MEDIUM |
| BSX |
Guide |
Q3'26 organic growth implied |
BETTER |
guide ~7-8% vs. cons ~6.5% (Q3'26) |
LOW |
| BSX |
Guide |
US EP/FARAPULSE + WATCHMAN stabilization commentary |
UNKNOWN |
pred US EP ~mid-single-digit vs. cons ~flat-to-LSD (Q2'26) |
LOW |
| BSX |
Guide |
Buyback executed / restructuring savings flow-through |
BETTER |
pred ~$2B repurchased + ~$500M gross savings vs. cons ~$0 buyback modeled (Q2'26/FY26) |
LOW |
| BSX |
Return |
Day-1 residual (stock − beta × S&P 500) |
+5.0% |
— |
MEDIUM |
| BSX |
Return |
5-day cumulative residual |
+5.5% (STABILIZE) |
Sentiment is washed out (stock -50% YTD, bounced ~8% off late-June lows into print) and the bar is set at guidance. A modest beat on organic/EPS plus a reaffirmed FY26 range and pre-announced restructuring (defends the double-digit EPS algo) should trigger a relief pop of ~+5%. Out-period math is roughly neutral-to-slightly-positive: a Q2 beat pulls FY estimates up modestly, but the FY organic range is only held (not raised) and 2H still needs to accelerate, so estimate revisions are small. After three prior disappointments the market stays skeptical—hence the initial gain largely holds rather than compounding (no strong follow-through), but there's no cut to force a fade. Net: the day-1 move stabilizes with only slight incremental drift, with fragility if any FARAPULSE/WATCHMAN datapoint disappoints. |
LOW |